

Corrigendum

Corrigendum to “Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of *Coptis chinensis* Franchin Polycystic Ovary Syndrome”

Jian Xiong Ma,^{1,2} Miaoyong Ye ,³ Ke Ma,¹ Kang Zhou,¹ Yingying Zhang,¹ Xiting Wang ,⁴ and Hongxuan Tong⁵

¹The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China

²Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China

³Department of Urology, The Affiliated Wenling Hospital of Wenzhou Medical University, Wenling, Zhejiang 317500, China

⁴School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China

⁵Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China

Correspondence should be addressed to Hongxuan Tong; thongxuan1@163.com

Received 11 November 2021; Accepted 11 November 2021; Published 28 November 2021

Copyright © 2021 Jian Xiong Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Network Pharmacology-Based Strategy for Predicting Active Ingredients and Potential Targets of *Coptis chinensis* Franchin Polycystic Ovary Syndrome” [1], there are errors in the following sections that were introduced during the preparation of the manuscript.

In the Abstract section, “These results indicated that WZYYP has a protective effect on spermatogenesis disorder, suggesting that it could be an alternative choice for male infertility therapy” should be corrected to “These results indicated that *Coptis chinensis* has a therapeutic effect on polycystic ovary syndrome, suggesting that it could be an alternative choice for polycystic ovary syndrome.”

In Section 2.9, “WZYYP” should be corrected to “*Coptis chinensis*.”

In the legend of Figure 7, “WZYYP” should be corrected to “*Coptis chinensis*.”

The authors apologise for these errors and confirm that this does not affect the results or conclusions of the article.

References

- [1] J. X. Ma, M. Ye, K. Ma et al., “Network pharmacology-based strategy for predicting active ingredients and potential targets of *Coptis chinensis* Franchin polycystic ovary syndrome,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2021, Article ID 6651307, 15 pages, 2021.